2022年临床微生物开放会议:评估临床实验室与产业界对COVID-19检测能力挑战的应对(第一部分)
随着COVID-19大流行消退,临床与公共卫生实验室及产业伙伴反思应对成败。临床微生物开放会议(CMO)汇集临床实验室主任、产业伙伴及CDC、FDA等机构,讨论初始应对、供应链限制、人员挑战、检测分诊与沟通、信息学需求、财务影响及EUA流程,并提出改进未来大流行应对的步骤。
要点
- 多利益相关方总结COVID-19检测能力挑战的经验教训
- 供应链与人员短缺是检测应对的主要瓶颈
- 提出改进未来大流行检测应对的初步建议
核心结论
- 会议总结了COVID-19大流行检测应对的成功与失败,并提出改进未来大流行应对的步骤。
研究设计与样本
- CMO会议汇集临床实验室主任、产业伙伴及CDC、FDA等州与联邦机构关键利益相关方进行讨论。
主要发现
- 讨论了初始大流行应对、激增期供应链限制、人员挑战、检测分诊与沟通策略、临床信息学需求、SARS-CoV-2检测的实验室财务影响及紧急使用授权流程。
临床怎么用
- 实验室与产业界可参考会议提出的步骤,优化未来大流行中的检测分诊、沟通及供应链应对。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
As the COVID-19 pandemic winds down, clinical and public health laboratories, along with industry partners, reflect on the successes and failures of the pandemic response. To capture the lessons learned and better prepare for the next pandemic, the Clinical Microbiology Open (CMO) assembled key stakeholders including directors of clinical laboratories, industry partners, and state and federal agencies such as the Centers for Disease Control and Prevention and the Food and Drug Administration. Participants were asked to provide their perspectives on the initial pandemic response, supply chain constraints especially during surges, staffing challenges, test triage and communication strategies, clinical informatics needs, laboratory financial impacts of SARS-CoV-2 testing, and the emergency use authorization process. This manuscript summarizes the diagnostic laboratory and industry perspectives on these issues that were presented and discussed at CMO and proposes some steps that could be taken to improve future pandemic responses.
引用
- Peaper DR, Doern CD, Sharp S, et al. Proceedings of the Clinical Microbiology Open 2022-assessing clinical laboratory and industry responses to COVID-19 pandemic testing capacity challenges (part 1). J Clin Microbiol. 2024. PMID: 38379142. doi:10.1128/jcm.00941-23
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。